Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort.

X Xiaolei Shi (Hebei Laboratory of Crop Genetics and Breeding, National Soybean Improvement Center Shijiazhuang Sub-Center, Ministry of Agriculture and Rural Affairs, Huang-Huai-Hai Key Laboratory of Biology and Genetic Improvement of Soybean, Institute of Cereal and Oil Crops, Hebei Academy of Agricultural and Forestry Sciences) M Mohammed Alshalalfa E Ella Boytim (Division of Hematology, Oncology and Transplantation, University of Minnesota) R R. Jeffrey Karnes D Daniel Eidelberg Spratt (University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH) A Amol C. Shetty H Hannah E. Bergom (Division of Hematology, Oncology and Transplantation, University of Minnesota) K Kristine Peregrino Lacuna (Memorial Sloan Kettering Cancer Center, New York, NY) S Susan Halabi (From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.), and the Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville (H.S., E.S.) — all in Maryland; the Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN (K.V.B., M.O., C.M., G.P.B.); AdventHealth Cancer Institute and the University of Central Florida, Orlando (G.S.); Dana–Farber/Harvard Cancer Center, Boston (S.B., B.M.); UNC Lineberger Comprehensive Cancer Center, Chapel Hill (W.Y.K.), and Duke University Medical Center and Duke Cancer Institute, Durham (J.H., S.H.) — both in North Carolina; the University of Kansas Cancer Center, Westwood (R.P.); Memorial Sloan Kettering Cancer Center, New York (M.Y.T., M.J.M., J.E.R.), and Roswell Park Comprehensive Cancer Center, Buffalo (G.C.) — both in...) N Nima Sharifi K Krishnan R. Patel (Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD) C Chad Tang (Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA) A Ashley Ross (Northwestern University Feinberg School of Medicine, Chicago) E Elai Davicioni E Emmanuel S. Antonarakis (Masonic Cancer Center, University of Minnesota) C Charles J. Ryan (Memorial Sloan Kettering Cancer Center, New York, NY) P Phuoc T. Tran J Justin Hwang (Masonic Cancer Center, University of Minnesota)

Abstract

382 Background: Androgen receptor signaling drives prostate cancer (PC) progression, and genes involved in androgen production, uptake, and conversion (APUC) are key therapeutic targets. We previously defined a 6-APUC gene set ( HSD3B1, HSD3B2, CYP3A43, CYP11A1, CYP11B1, and CYP17A1 ), that identified metastatic PC with favorable prognosis and predict docetaxel benefit. However, the expression landscape and clinical relevance of APUC genes have not been interrogated in localized PC. Methods: We analyzed the expression of 21 APUC genes in 55,329 radical prostatectomy tumor samples that underwent Decipher prostate genomic classifier (GC) testing (Veracyte Inc) between 2016-2024. Baseline clinical/pathologic factors were retrieved from Decipher GRID database (NCT02609269). Associations between gene expression quartiles with PathoGenomic Risk Factors (PGRF) including Very High Decipher score >0.85 (VHD), Grade Group (GG) 4-5, LNI and SVI were examined. Associations with distant metastatic (DM) outcomes and metastasis free survival (MFS) were evaluated using logistic regression in Mayo545 and Cox regression in Meta855 RP cohorts, respectively. Results: High expression of SRD5A2 was associated with favorable PGRF (lower odds ratio (OR), p<0.0001), lower rate of development of DM (OR 0.36, p<0.05), and longer MFS (Hazard ratio (HR) 0.51, p<0.05). HSD17B6 showed similar results for PGRF (lower OR, p<0.0001), DM (OR 0.58, p<0.05) and longer MFS (HR 0.39, p<0.05) despite being associated with GG4-5 and SVI+ in samples with VHD. In contrast, high expression of SRD5A3 and HSD17B10 had high OR for PGRFs (p<0.0001). High expression of SLCO2B1 , an androgen uptake gene, had the strongest association with GG4-5 and SVI/LNI (p<0.001 for both). We noted that SRD5A2 lacked correlation with SRD5A1 and SRD5A3 , which instead correlated with each other. Compared to all APUC genes, SRD5A2 had limited correlations with almost all APUC genes, including ones that exhibited robust cross correlation with each other . Similar to our prior finding, most APUC genes demonstrated negative correlation with AR expression and AR activity signatures. Key outcomes were validated based on transcriptomic data from 492 samples from TCGA database. Conclusions: Comprehensive analysis of 21 APUC genes in over 55,000 PC identified distinct, context-dependent associations with metastatic outcomes and clinical and molecular risk factors. Notably, high SRD5A2 expression was associated with lower odds of high-risk features and metastatic outcomes, whereas SRD5A1 and SRD5A3 linked to adverse outcomes, suggesting critical yet divergent roles among 5-alpha-reductase family members. These findings underscoring androgen-metabolic heterogeneity and highlighting SRD5A2 as a potential biomarker of indolent biology in localized prostate cancer.

Article Details

Volume / Issue Vol. 44, Issue 7_suppl
Published March 01, 2026
Pages 382-382
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (18)

X

Xiaolei Shi

Hebei Laboratory of Crop Genetics and Breeding, National Soybean Improvement Center Shijiazhuang Sub-Center, Ministry of Agriculture and Rural Affairs, Huang-Huai-Hai Key Laboratory of Biology and Genetic Improvement of Soybean, Institute of Cereal and Oil Crops, Hebei Academy of Agricultural and Forestry Sciences

M

Mohammed Alshalalfa

E

Ella Boytim

Division of Hematology, Oncology and Transplantation, University of Minnesota

R

R. Jeffrey Karnes

D

Daniel Eidelberg Spratt

University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH

A

Amol C. Shetty

H

Hannah E. Bergom

Division of Hematology, Oncology and Transplantation, University of Minnesota

K

Kristine Peregrino Lacuna

Memorial Sloan Kettering Cancer Center, New York, NY

S

Susan Halabi

From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda (A.B.A., N.S., S.N., L.L., L.C.), the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (J.H.-C.), and the Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Rockville (H.S., E.S.) — all in Maryland; the Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN (K.V.B., M.O., C.M., G.P.B.); AdventHealth Cancer Institute and the University of Central Florida, Orlando (G.S.); Dana–Farber/Harvard Cancer Center, Boston (S.B., B.M.); UNC Lineberger Comprehensive Cancer Center, Chapel Hill (W.Y.K.), and Duke University Medical Center and Duke Cancer Institute, Durham (J.H., S.H.) — both in North Carolina; the University of Kansas Cancer Center, Westwood (R.P.); Memorial Sloan Kettering Cancer Center, New York (M.Y.T., M.J.M., J.E.R.), and Roswell Park Comprehensive Cancer Center, Buffalo (G.C.) — both in...

N

Nima Sharifi

K

Krishnan R. Patel

Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

C

Chad Tang

Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

A

Ashley Ross

Northwestern University Feinberg School of Medicine, Chicago

E

Elai Davicioni

E

Emmanuel S. Antonarakis

Masonic Cancer Center, University of Minnesota

C

Charles J. Ryan

Memorial Sloan Kettering Cancer Center, New York, NY

P

Phuoc T. Tran

J

Justin Hwang

Masonic Cancer Center, University of Minnesota